The Week in Review: Nov 25 – Dec 2, 2016

Friday, December 2, 2016 News Recap Top of the news is that both Canada (Information Update – Direct-acting antivirals, used for hepatitis C, may reactivate hepatitis B) and Europe (EU health regulator warns some hep C drugs could reactivate hep B) are warning of the possibility of HBV reactivation from HCV DAA therapy.  The first warnings came out in April 2016 at EASL and then the US FDA issued warnings in October 2016. In a press release, Health C...

EU health regulator warns some hep C drugs could reactivate hep B

The European Medicines Agency warned on Friday that some of the most successful hepatitis C treatments on the market could reactivate hepatitis B in patients, the second time this year it has raised safety concerns over these treatments. The latest health warning covers some of the top-selling products in the multi-billion dollar hepatitis C market, including Sovaldi, Exviera, Viekirax, Olysio and Daklinza. These drugs cure well over 90 percent of pati

Information Update – Direct-acting antivirals, used for hepatitis C, may reactivate hepatitis B

OTTAWA, Dec. 1, 2016 /CNW/ - A recent Health Canada safety review found that patients infected with both hepatitis B and hepatitis C viruses who are being treated for hepatitis C with direct-acting antivirals may experience a reactivation of their hepatitis B. Hepatitis B reactivation is the return of an active hepatitis B infection, which can lead to serious complications such as liver failure. As a result, Health Canada is working with manufacturers to

FDA Adds Boxed Warning to Hepatitis C Drugs, Warns of Hepatitis B Reactivation Risk

Safety Announcement The U.S. Food and Drug Administration (FDA) is warning about the risk of hepatitis B virus (HBV) becoming an active infection again in any patient who has a current or previous infection with HBV and is treated with certain direct-acting antiviral (DAA) medicines for hepatitis C virus. In a few cases, HBV reactivation in patients treated with DAA medicines resulted in serious liver problems or death. As a result, we ar...

U.S.: Hepatitis C Treatment Panel Calls For Hepatitis B Testing

A new update to the guidelines for the treatment of hepatitis C recommends testing for the hepatitis B virus in all patients who are planning treatment with direct acting antiviral drugs. Hepatitis B (HBV) and C (HVC) are diseases caused by different viruses that can both start as acute infections but turn chronic in some people, eventually leading to life-threatening liver damage, according to the Centers for Disease Control and Prevention. While there a